HRTX Heron Therapeuti
Company Analysis
Latest News
🔴 Heron Therapeutics is trading 5.66% down today — no fresh company-specific announcement identified
Heron Therapeutics is trading 5.66% down at $0.30, with no fresh company-specific announcement identified for August 26, 2026. - Its latest material company...
🟢 Heron Therapeutics rises 5.2% — Biotech Sector Continues Upward Trend on Strong Momentum
With Biotech (XBI) up 2.0%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Heron Therapeutics rises 5.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Heron Therapeutics is trading 5.2% down today after revenue miss and guidance withdrawal
Heron Therapeutics is trading 5.2% down at $0.30, following recent pressure after second-quarter revenue missed expectations and management withdrew full-year...
🔴 Heron Therapeutics is trading 7.13% down today with no fresh company-specific catalyst identified
Heron Therapeutics is trading at $0.31 (-7.13%) now, with no fresh company-specific catalyst directly explaining the August 17, 2026 decline identified. • The...
🟢 Heron Therapeutics is trading 6.5% up in pre-market after extending Tax Benefit Preservation Plan through 2029
Heron Therapeutics is trading at $0.36, up +6.47% in pre-market after amending its Tax Benefit Preservation Plan. - The plan is designed to preserve the...
Heron Therapeutics Extends Tax Benefit Preservation Plan to August 2029
Heron Therapeutics, Inc. has amended its Tax Benefit Preservation Plan, effectively extending its expiration date by three years. The plan, which acts as a...
🔴 Heron Therapeutics is trading 5.5% down today after guidance withdrawal and CINVANTI patent uncertainty
Heron Therapeutics is trading 5.51% down now at $0.32 after investors continued assessing the August 10 earnings miss and withdrawal of full-year 2026...
🟢 Heron Therapeutics is trading 10.93% up today rebounding after post-earnings decline
Heron Therapeutics is trading 10.93% up at $0.36, rebounding as broader risk-on sentiment appears to support the move. - Shares closed at $0.32 on August 11,...
🟢 Heron Therapeutics is trading 5.9% up today with no identified company-specific catalyst
Heron Therapeutics is trading $0.34, up 5.90%, with no new company-specific announcement identified for August 12, 2026. - The August 10 earnings miss,...
🔴 Heron Therapeutics is trading 7.1% down today after Q2 revenue miss and full-year guidance withdrawal
Heron Therapeutics is trading 7.1% down now at $0.31 after its August 10, 2026 earnings release reported a revenue miss and the company withdrew full-year...
🔴 Heron Therapeutics is trading 23.82% down today after missing Q2 revenue and earnings expectations
Heron Therapeutics is trading 23.82% down now at $0.37 after its August 10, 2026, second-quarter results missed revenue and earnings expectations. - Revenue...
Heron Therapeutics Yanks Its 2026 Outlook and Hunts for a Lifeline — Is This a Turnaround Story or a Company Running Out of Road?
Shares of Heron Therapeutics cratered 13.5% to $0.42 Monday morning after the biotech missed second-quarter expectations and pulled its full-year guidance — a...
🔴 Heron Therapeutics is trading 13.53% down in pre-market after second-quarter 2026 revenue missed estimates
Heron Therapeutics is trading 13.53% down at $0.42 after second-quarter 2026 revenue missed expectations at $37.7 million versus the $42.19 million consensus...
🔴 Heron Therapeutics is trading 6.21% down in pre-market after Q2 revenue and earnings misses
Heron Therapeutics is trading 6.21% down in pre-market at $0.46 after its August 10, 2026 second-quarter report missed revenue and earnings expectations. -...
Heron Therapeutics misses second quarter 2026 estimates and withdraws full-year financial guidance
Heron Therapeutics reported second quarter 2026 results that missed analyst expectations on both the top and bottom lines. Management withdrew its previously...
Heron Therapeutics Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
Consensus estimates for Heron Therapeutics anticipate a Q2 2026 loss of $0.02 per share on revenue of $42.19 million, with the stock currently trading near...
🟢 Heron Therapeutics is trading 10% up in pre-market with second-quarter results scheduled for August 10, 2026
Heron Therapeutics is trading 10.22% up at $0.55 in pre-market, with second-quarter results scheduled for August 10, 2026. - The company has not announced...
🟢 Heron Therapeutics is trading 6% up today amid biotech sector strength
Heron Therapeutics is trading 6% up at $0.54 in pre-market, as the stock benefits from ongoing biotech sector strength and a broader risk-on tone in U.S....
🟢 Heron Therapeutics is trading 5.3% up today amid broad market and biotech strength
Heron Therapeutics is trading 5.3% up at $0.54 amid a broad risk-on rally in U.S. equities and strength in biotech stocks. • The move appears driven by...